RT Journal Article
SR Electronic
T1 Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort
JF Lupus Science & Medicine
JO Lupus Sci Med
FD Lupus Foundation of America
SP e000667
DO 10.1136/lupus-2022-000667
VO 9
IS 1
A1 May Y Choi
A1 Ann Elaine Clarke
A1 Katherine Buhler
A1 Michelle Jung
A1 Hannah Mathew
A1 Meifeng Zhang
A1 Francesca S Cardwell
A1 Heather Waldhauser
A1 Marvin J Fritzler
YR 2022
UL http://lupus.bmj.com/content/9/1/e000667.abstract
AB Cytokine autoantibodies, particularly those directed to type I interferon (T1IFN), have been reported to portend an increased risk of severe COVID-19. Since SLE is one of the conditions historically associated with T1IFN autoantibodies, we sought to determine the prevalence of cytokine autoantibodies in our local cohort of 173 patients with SLE prepandemic and intrapandemic, of which nine had confirmed exposure to SARS-CoV-2. Autoantibodies to 16 different cytokines, including T1IFN, were measured by an addressable laser bead immunoassay. None of the 9 patients with confirmed exposure to SARS-CoV-2 had autoantibodies to T1IFN and none had severe COVID-19 symptoms, necessitating hospitalisation. Hence, we could not confirm that TIIFN autoantibodies increase the risk for severe COVID-19. In addition, the cytokine autoantibody pattern did not differ between those with and without evidence of SARS-CoV-2 exposure.